A.N. Chremos

Famotidine, a New, Potent, Long-Acting Histamine H2-Receptor Antagonist: Comparison With Cimetidine and Ranitidine in the Treatment of Zollinger-Ellison Syndrome

John M. Howard, A.N. Chremos, Martin J. Collen et al. · Gastroenterology · 1985 · 186 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin

Carlos A. Dujovne, A.N. Chremos, James L. Pool et al. · The American Journal of Medicine · 1991 · 111 citations

Medicine, Pharmacology, Pharmacotherapy +7

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins.

Charles L. Shear, Frank A. Franklin, Sandra S. Stinnett et al. · Circulation · 1992 · 82 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Effects of sulindac and indomethacin on renal prostaglandin synthesis

John R. Sedor, Susan L. Williams, A.N. Chremos et al. · Clinical Pharmacology & Therapeutics · 1984 · 71 citations

Medicine, Pharmacology, Pharmacotherapy +14

Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man

J H Lin, A.N. Chremos, K. C. Yeh et al. · European Journal of Clinical Pharmacology · 1988 · 51 citations

Pharmacy, Pharmacokinetics, Pharmacology +14